Peritoneal carcinomatosis of colorectal origin Is there a role for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?

S Zerhouni, J Andrea McCart - Oncology exchange, 2012 - search.ebscohost.com
Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) origin carries a dismal prognosis,
as evidenced by a 5-year survival of less than 15% in patients treated with systemic …

Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal …

CS Chia, GHC Tan, C Lim, KC Soo… - Annals of surgical oncology, 2016 - Springer
Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy
(HIPEC) is becoming accepted treatment for peritoneal carcinomatosis (PC) from colorectal …

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience

LH Iversen, PC Rasmussen… - Colorectal …, 2013 - Wiley Online Library
Aim Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy
(HIPEC) is a treatment option with curative intent for selected patients with peritoneal …

[HTML][HTML] Cytoreductive surgery versus systemic chemotherapy alone in isolated peritoneal carcinomatosis of colorectal origin

M Ozcelik, A Oyman, I Cil, O Duzgun, OF Ozkan… - Age, 2021 - jcpsp.pk
Objective: To compare the overall survival and progression-free survival of front-line
cytoreductive surgery (CRs)±hyperthermic intraperitoneal chemotherapy versus intensive …

Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis

J Franko, Z Ibrahim, NJ Gusani, MP Holtzman… - Cancer, 2010 - Wiley Online Library
BACKGROUND: Survival benefit of cytoreductive surgery combined with hyperthermic
intraperitoneal chemoperfusion was demonstrated by a prospective randomized trial for …

[HTML][HTML] Repeated cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy in patients with peritoneal carcinomatosis: A retrospective cohort study

C Paasch, G De Santo, HN Gamal-Eldin… - Annals of Medicine and …, 2021 - Elsevier
Introduction The prognosis of abdominal cancer with peritoneal carcinomatosis (PC) is poor.
In literature, some authors described a repeated Cytoreductive Surgery (CRS) with …

Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study

D Goéré, A Souadka, M Faron, AS Cloutier… - Annals of surgical …, 2015 - Springer
Background The main prognostic factors after complete cytoreductive surgery (CCRS) of
colorectal peritoneal carcinomatosis (PC) followed by intraperitoneal chemotherapy (IPC) …

Short-term complications in elderly patients undergoing CRS and HIPEC: a single center's initial experience

A Oemrawsingh, NL de Boer… - European Journal of …, 2019 - Elsevier
Introduction Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy
(HIPEC) is a well-established curative treatment for patients with peritoneal carcinomatosis …

[HTML][HTML] Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis

N Vassos, T Förtsch, A Aladashvili… - World Journal of …, 2016 - Springer
Background Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy
(HIPEC) has become the treatment of choice for resectable peritoneal carcinomatosis (PC) …

Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal …

W Ceelen, Y Van Nieuwenhove, DV Putte… - Annals of surgical …, 2014 - Springer
Background In selected patients with colorectal peritoneal carcinomatosis (PC),
cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) may …